Community Engagement

In 2017, a groundbreaking study challenged the global vaccine system.The Vaccine Manufacturing and Procurement in Africa (VMPA) study (PDF) confirmed what many already knew on the ground: Even when African countries invest in local vaccine manufacturing, they’re still being locked out of the very systems meant to deliver vaccines to their own people. Procurement barriers.

To deliver vaccines equitably, we need more than just doses. We need a system. The Access Problem Isn’t Just Supply. It’s Systems. Vaccines don’t save lives on their own. Delivery does. Across Nigeria, millions of children remain unvaccinated not because vaccines don’t exist, but because delivery breaks down: cold-chain gaps, health worker shortages, distance, and

At LunaVax, we’re preparing to evaluate a new way of delivering vaccines in Lagos, Abuja (FCT), Adamawa and Anambra, with something as small as a patch. Microneedle vaccine patches (MAPs) are an emerging innovation that could help make vaccines safer, simpler and easier to deliver, especially in communities with limited access to cold chains, trained

LunaVax’s MR-MAP study in Nigeria At LunaVax, we believe innovation in global health doesn’t end in the lab. It begins when new tools reach the communities that need them most. LunaVax is preparing a planned Phase III measles-rubella microarray patch (MR-MAP) effectiveness-implementation trial in Nigeria. The study will evaluate whether the patch protects children as